MENU
CLLS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Cellectis SA (CLLS) Ownership - Who owns Cellectis SA?
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
8, rue de la Croix Jarry
Phone
+33 181691600
Employees
285
Web
https://www.cellectis.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
270.76M
P/E Ratio
N/A
Total Cash
241.69M
Projected Growth
N/A
Total Debt
91.77M
Revenue
47.63M
Risk (Beta)
3.85
Dividend Yield
N/A
Total Cash/Share
2.41
Total Debt/Equity
N/A
Revenue/Share
0.56 USD as % of share price
Fundamentals
CLLS
Capitalization
271M
P/E Ratio
N/A
Risk (Beta)
3.85
Dividend Yield
N/A
Total Cash
242M
Total Cash/Share
2.41
Total Debt
91.8M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.56%
Revenue
47.6M
ROE
N/A
Book Value
116M
P/B Ratio
2.80
Cash Flow
N/A
Earnings
-0.67
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
5.9M
Current Ratio
1.67
Current Revenue Per Employee
47995.50
Dividends Per Share - Security
N/A
EBITDA
-32.49M
Float
N/A
Float - Current
N/A
Gross Income Margin
81.09
Revenue To Assets
-16.85
Shares Held By Institutions
19.8M
Shares Outstanding - Current
100M
Total Liabilities
248M
Total Volume MTD
N/A
Value
N/A
Gain YTD
50.556
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CLLS showed earnings on August 04, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information
General Information
a genome engineering company of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
8, rue de la Croix Jarry
Phone
+33 181691600
Employees
285
Web
https://www.cellectis.com